-
公开(公告)号:US20240199594A1
公开(公告)日:2024-06-20
申请号:US18365392
申请日:2023-08-04
Applicant: Genentech, Inc.
Inventor: Marie-Gabrielle BRAUN , Emily HANAN , Steven T. Staben , Robert Andrew HEALD , Calum MACLEOD , Richard ELLIOTT
IPC: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.-
公开(公告)号:US20160264596A1
公开(公告)日:2016-09-15
申请号:US15157734
申请日:2016-05-18
Applicant: Hoffmann-La Roche Inc.
Inventor: Katrin Groebke Zbinden , Roger Norcross , Philippe Pflieger
IPC: C07D495/04 , C07D295/135 , C07D263/32 , C07D401/12 , C07D211/26 , C07D207/12 , C07D207/10 , C07D265/30 , C07D401/14 , C07D403/12 , C07D413/12 , C07D417/12 , C07D413/14 , C07D417/14 , C07D267/10 , C07D207/09
CPC classification number: C07D207/09 , A61K9/2018 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04
Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof.Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
Abstract translation: 式I化合物对微量胺相关受体(TAAR)具有良好的亲和力,特别是TAAR1。 该化合物可用于治疗抑郁症,焦虑障碍,双相情感障碍,注意力缺陷多动障碍(ADHD),应激相关疾病,精神病性精神障碍如精神分裂症,神经系统疾病如帕金森病,神经变性疾病如阿尔茨海默病, 癫痫,偏头痛,高血压,药物滥用和代谢障碍如进食障碍,糖尿病,糖尿病并发症,肥胖症,血脂异常,能量消耗和同化障碍,体温平衡紊乱和失调,睡眠和昼夜节律紊乱以及心血管疾病 。
-
公开(公告)号:US20110152245A1
公开(公告)日:2011-06-23
申请号:US12969613
申请日:2010-12-16
Applicant: Katrin Groebke Zbinden , Roger Norcross , Philippe Pflieger
Inventor: Katrin Groebke Zbinden , Roger Norcross , Philippe Pflieger
IPC: A61K31/40 , C07D207/09 , C07D295/135 , C07D413/12 , C07D401/12 , C07D207/12 , C07D211/26 , C07D413/14 , C07D417/14 , C07D267/08 , A61K31/495 , A61K31/496 , A61K31/5377 , A61K31/454 , A61K31/4439 , A61K31/451 , A61K31/553 , A61P25/00 , A61P25/24 , A61P25/18 , A61P25/16 , A61P25/22
CPC classification number: C07D207/09 , A61K9/2018 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04
Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof.Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
Abstract translation: 本发明涉及下式的化合物,其中R,R 1,R 2,X和Y如本文所定义,及其药学上合适的酸加成盐。 式I化合物对微量胺相关受体(TAAR)具有良好的亲和力,特别是TAAR1。 这些化合物可用于治疗抑郁症,焦虑障碍,双相情感障碍,注意力缺陷多动障碍(ADHD),应激相关疾病,精神病性精神障碍如精神分裂症,神经系统疾病如帕金森病,神经变性疾病如阿尔茨海默病, 癫痫,偏头痛,高血压,药物滥用和代谢障碍如进食障碍,糖尿病,糖尿病并发症,肥胖症,血脂异常,能量消耗和同化障碍,体温平衡紊乱和失调,睡眠和昼夜节律紊乱以及心血管疾病 。
-
公开(公告)号:US3342786A
公开(公告)日:1967-09-19
申请号:US57041766
申请日:1966-08-05
Applicant: ROHM & HAAS
Inventor: EMMONS WILLIAM D
IPC: C07D265/32 , C07D267/08 , C08F20/34 , C08F20/36 , C10L1/14 , C10L1/22 , C10L1/24 , C10M149/10 , D04H1/64 , D06M15/267 , H01B3/44
CPC classification number: H01B3/44 , C07D265/32 , C07D267/08 , C08F20/34 , C08F20/36 , C10L1/146 , C10L1/2368 , C10L1/2468 , C10M149/10 , C10M2205/026 , C10M2207/023 , C10M2207/026 , C10M2207/123 , C10M2207/125 , C10M2207/129 , C10M2207/144 , C10M2207/146 , C10M2207/22 , C10M2207/282 , C10M2207/34 , C10M2209/00 , C10M2209/02 , C10M2209/084 , C10M2209/10 , C10M2209/101 , C10M2209/108 , C10M2209/109 , C10M2215/04 , C10M2215/06 , C10M2215/066 , C10M2215/224 , C10M2215/26 , C10M2217/028 , C10M2217/06 , C10M2219/022 , C10M2219/024 , C10M2219/044 , C10M2219/087 , C10M2219/088 , C10M2219/089 , C10M2219/108 , C10M2223/041 , C10M2223/045 , C10M2227/061 , C10M2229/02 , C10M2229/05 , C10M2290/02 , C10N2210/02 , C10N2210/08 , C10N2240/02 , C10N2240/08 , C10N2250/10 , D04H1/587 , D04H1/64 , D06M15/267 , Y10S424/02
Abstract: Polymers or copolymers of the unsaturated carboxylic esters of formula in which R is a hydrogen atom or methyl group, m is 1, 2 or 3, p is 1, 2, 3 or 4, x is 1, 2, 3 or 4, A is an alkylene group (2-4C) and Z is a substituted morpholinone group or a substituted glycine group in which Y is an alkylene group (2 or 3C); either R1 is a hydrogen atom, an alkyl group (1-8C), or a phenyl group and R2 is hydrogen, an alkyl group (1-8C) or R1 and R2 are joined in a ring of 5 to 7 C atoms with the proviso that when p is greater than 1 then m is 1, and when m is greater than 1 then R is hydrogen (see Division C2) are prepared by vinyl addition processes. Hydrolysis of the cyclic radical to form the glycine radical during the polymerization in aqueous media varies with the temperature and acidity or alkalinity of the medium, or the hydrolysis may be brought about after polymerization by heating in aqueous medium. Conventional free-radical catalysts may be used and copolymers with H2C=C in which R is a hydrogen atom or a methyl group, m is 1,2, or 3; p is 1,2,3 or 4; #c is 1,2,3 or 4; A is an alkylene group (2-4 C); and Z is a substituted morpholinone group or a substituted glycine group in which Y is an alkylene group (2-3 C); R1 is hydrogen, alkyl (1-8 C), or phenyl group; R2 is hydrogen, alkyl (1-8 C) or R1 and R2 may be joined to form a 5-7 C ring; providing that when p is greater than 1 then m is 1, and when m is greater than 1 R is hydrogen, specifically N - (b - methacryloxyethyl) - 2 - morpholinone, N - (b - acyloxyethyl) - 2 - morpholinone, N - [b - (4 - pentenoyloxy)ethyl] - 2 - morpholinone or mixtures thereof. The esters are prepared by reacting in which R0 is an alkyl group with an N-substituted morpholinone-2 under transesterifying conditions e.g. in presence of tetra alkyl titanate or an alkali metal (C1-C4)-alkoxide. Alternatively, an acyl halide may be reacted with the N-substituted morpholinone-2, e.g. in the presence of a hydrogen halide acceptor. The ester may be hydrolysed to form a compound with Z a substituted glycine group. The N-substituted-morpholinone-2 may be prepared by reacting an alkylene oxide (2-4 C) with a compound where M is an alkali metal and acidifying and dehydrating the intermediate formed, or by reacting the alkylene oxide with a hydroxy-(poly)-alkoxyamine H(OA)#c-NH2 (#c=2-4), followed by reaction with an alkali metal a -chloro-acetate. The ester products are normally stable, colourless liquids which may form addition linear polymers, or copolymers with vinyl monomers. Examples describe the preparation of the compounds specified above and N - [b - (3 - pentenoyloxy)propyl] - 3,3 - dimethyl - 2 - morpholinone, N - [3 - (crotonoxypropyl] - 5 - methyl - 2 morpholinone, N - (acyloxyethoxyethyl) - 2 - morpholinone, N - (methacryloxypropoxypropyl) - 3 - phenyl - 2 - morpholinone, and N-(5-hexenoyloxyethoxyethoxyethoxyethyl) -2-morpholinone and their hydrolysis to the corresponding glycines.ALSO:Polymers or copolymers of the unsaturated carboxylic esters of formula in which R is a hydrogen atom or a methyl group; m is 1, 2 or 3; p is 1, 2, 3 or 4; x is 1, 2, 3 or 4; A is an alkylene group (2-4C) and Z is a substituted morpholinone group or a substituted glycine group which Y is an alkylene group (2 or 3C); either R1 is a hydrogen atom, an alkyl group (1-8c) or a phenyl group and R2 is hydrogen-an alkyl group (1-8C) or R1 and R2 are joined in a ring of 5 to 7C atoms with the proviso that when p is greater than 1 then m is 1, and when m is greater than 1 then R is a hydrogen atom (see Divns C2 and C3) may be used to coat substrates much as wood or metal, e.g. steel plate, a copper wire or glass. Conventional comonomers are specified together with usual additives and the coatings which may be on either bare or primed surfaces (with alkyd, epoxy or aminoplast primers) may be cured by heating with or without a catalyst. Examples describe the coating of steel with a copolymer of methyl methacrylate, ethyl acrylate and N-(B-methacryloxyethyl)-2-morpholinone; methyl methacrylate, butyl methacrylate, N-[B-(4-pentenoyl-oxy) ethyl]-2-morpholinone; methyl methacrylate, vinyl toluene, 2-ethylhexyl methacrylate and N-[3-(crolonoxy) propyl]-5-methyl-2-morpholinone; and vinyl acetate, vinyl chloride, styrene, butyl acrylate and N-[B-(3-pentenoyloxy)propyl]-3, 3-di-methyl-2-morpholinone; aluminium or wood with a copolymer of methyl and butyl methacrylate and N-(B-methacryloxyethyl)-2-morpholinone; and the enamelling of copper wire by passing through a latex prepared by polymerising a solution of the hydrolysis product of N-(diglycol)-2-morpholinone with N-methoxymethyl-methacrylamide, acrylonitrile and butyl acrylate, to which is added dimethyl formamide.ALSO:Polymers or copolymers of the unsaturated carboxylic esters of formula: in which R is a hydrogen atom or a methyl group; m is 1, 2 or 3; p is 1, 2, 3 or 4; x is 1, 2, 3 or 4; A is an alkylene group (2-4C) and Z is a substituted morpholine group: or a substituted glycine group: in which Y is an alkylene group (2 or 3C); either R1 is a hydrogen atom, an alkyl group (1-8c) or a phenyl group and R2 is hydrogen, an alkyl group (1-8c) or R1 and R2 are joined in a ring of 5 to 7C atoms with the proviso that when p is greater than 1 then m is 1, and when m is greater than 1 then R is a hydrogen atom (see Divisions C2 and C3) may be used to treat textiles, (e.g. bonding non-woven fabrics, shrink proofing wool and crease-proofing cotton and rayon), paper (e.g. p to increase wet strength or as a binder in mineral coating. Conventional comonomers are specified together with usual additives and the compositions may be cured in situ with heat and with or without a catalyst. Examples describe the bonding of non-woven fabric of carded viscose fibres with an aqueous dispersion of a copolymer from N-(5-hexenoyloxyethoxy ethoxyethoxyethyl) - 2 - morpholinone, ethyl acrylate, acrylamide and N-methylolacrylamide which is cured thereon; the sizing of yarns of cotton, rayon, wool, nylon and cellulose acetate with aqueous solutions of hydrolysis products of N-(B-methacryloxyethyl)2-morpholinone, N-(B-acryloxyethyl)-2-morpholinone, N-[B-(3-pentenoyloxy) propyl]-3, 3-di-methyl-2-morpholinone, N-[3-(crotonxy) propyl]-5-methyl-2-morpholinone, N-(acyloxyethoxyethyl)-2-morpholinone, N-(methacryloxypro poxypropyl))-3-phenyl-2-morpholinone, and N-(5-hexenoyloxyethoxyethoxyethoxyethyl) - 2 - morpholinone which are directly polymerised without isolation of the hydrolysed monomer. The size is water-soluble, and may be removed by normal scouring.
-
公开(公告)号:US11760753B2
公开(公告)日:2023-09-19
申请号:US17075583
申请日:2020-10-20
Applicant: Genentech, Inc.
Inventor: Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04 , A61P11/00 , A61P15/00 , A61P35/00 , A61P43/00 , A61K45/06 , C07B43/06
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.-
6.
公开(公告)号:US20170015678A1
公开(公告)日:2017-01-19
申请号:US15200301
申请日:2016-07-01
Applicant: Genentech, Inc.
Inventor: Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: C07D498/04 , A61K31/553
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
Abstract translation: 本文描述了具有式(I)结构的磷酸肌醇-3激酶(PI3K)调节活性或功能的苯并氧氮杂恶唑烷酮化合物:或其立体异构体,互变异构体或其药学上可接受的盐,以及本文所述的取代基和结构特征。 还描述了包括式I化合物的药物组合物和药物,以及将PI3K调节剂单独使用并与其它治疗剂联合用于治疗介导或依赖于PI3K调节异常的疾病或病症的方法。
-
公开(公告)号:US20160096846A1
公开(公告)日:2016-04-07
申请号:US14872787
申请日:2015-10-01
Applicant: Gilead Sciences, Inc.
Inventor: Britton Kenneth Corkey , Elfatih Elzein , Michael Graupe , Juan Guerrero , Robert H. Jiang , Rao V. Kalla , Dmitry Koltun , Xiaofen Li , Ruben Martinez , Eric Q. Parkhill , Thao Perry , Chandrasekar Venkataramani , Jeff Zablocki
IPC: C07D498/04 , C07D413/04 , C07D413/14 , C07D413/06 , C07D471/04 , C07B59/00 , C07D419/06 , C07D243/14 , C07D403/06 , C07D487/04 , C07D417/14 , C07D267/14 , C07D291/08
CPC classification number: C07D413/06 , A61K31/5513 , A61K31/553 , C07B59/002 , C07B2200/05 , C07D243/14 , C07D243/24 , C07D267/08 , C07D267/14 , C07D291/08 , C07D403/06 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/14 , C07D419/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
-
公开(公告)号:US08598168B2
公开(公告)日:2013-12-03
申请号:US11696880
申请日:2007-04-05
Applicant: Oscar Moradei , Isabelle Paquin , Sylvie Frechette , Tammy Mallais , Simon Roy , Roger Machaalani , Arkadii Vaisburg , Jeffrey M Besterman , Pierre Tessier , David Smil , Silvana Leit , Robert Déziel
Inventor: Oscar Moradei , Isabelle Paquin , Sylvie Frechette , Tammy Mallais , Simon Roy , Roger Machaalani , Arkadii Vaisburg , Jeffrey M Besterman , Pierre Tessier , David Smil , Silvana Leit , Robert Déziel
IPC: A61K31/535 , A61K31/445 , A61K31/44 , A61K31/42 , A61K31/415 , A61K31/40 , A61K31/28
CPC classification number: C07D333/36 , C07C235/56 , C07C237/40 , C07C271/28 , C07D207/12 , C07D207/14 , C07D207/325 , C07D209/08 , C07D213/40 , C07D213/56 , C07D213/61 , C07D213/89 , C07D267/08 , C07D277/28 , C07D277/36 , C07D295/155 , C07D307/52 , C07D317/58 , C07D333/20 , C07D333/28 , C07D333/38 , C07D333/70 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/08
Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
-
公开(公告)号:US20090239839A1
公开(公告)日:2009-09-24
申请号:US12391520
申请日:2009-02-24
Applicant: Fumio ITOH , Shuji Hinuma , Naoyuki Kanzaki , Hiroshi Mabuchi , Hiromi Yoshida , Hirokazu Matsumoto , Takeshi Wakabayashi
Inventor: Fumio ITOH , Shuji Hinuma , Naoyuki Kanzaki , Hiroshi Mabuchi , Hiromi Yoshida , Hirokazu Matsumoto , Takeshi Wakabayashi
IPC: A61K31/553 , A61P25/04
CPC classification number: C07D267/08
Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.
Abstract translation: 用于调节RFRP受体功能的试剂,其特征在于含有由式(I)表示的化合物[其中环A表示任选取代的芳环; 环B表示任选取代的苯环; X表示氧,S(O)n(n为0〜2的整数)或NR 3(R 3表示氢,任选取代的烃基或任意取代的杂环基)。 并且R 1和R 2各自表示氢,任选取代的烃基或任选取代的杂环基]或该化合物的盐。
-
公开(公告)号:US20070129348A1
公开(公告)日:2007-06-07
申请号:US10553273
申请日:2004-04-15
Applicant: Fumio Itoh , Shuji Hinuma , Naoyuki Kanzaki , Hiroshi Mabuchi , Hiromi Yoshida , Hirokazu Matsumoto , Takeshi Wakabayashi
Inventor: Fumio Itoh , Shuji Hinuma , Naoyuki Kanzaki , Hiroshi Mabuchi , Hiromi Yoshida , Hirokazu Matsumoto , Takeshi Wakabayashi
IPC: A61K31/554 , A61K31/553 , A61K31/5513
CPC classification number: C07D267/08
Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.
Abstract translation: 用于调节RFRP受体功能的试剂,其特征在于含有由式(I)表示的化合物[其中环A表示任选取代的芳环; 环B表示任选取代的苯环; X表示氧,S(O)n N(n为0〜2的整数)或NR 3(R 3)表示氢, 任选取代的烃基或任选取代的杂环基); 和R 1和R 2各自表示氢,任选取代的烃基或任选取代的杂环基]或该化合物的盐。
-
-
-
-
-
-
-
-
-